WO2005097192A3 - Active substance combination of a carbinol compound and an opioid - Google Patents

Active substance combination of a carbinol compound and an opioid Download PDF

Info

Publication number
WO2005097192A3
WO2005097192A3 PCT/EP2005/003862 EP2005003862W WO2005097192A3 WO 2005097192 A3 WO2005097192 A3 WO 2005097192A3 EP 2005003862 W EP2005003862 W EP 2005003862W WO 2005097192 A3 WO2005097192 A3 WO 2005097192A3
Authority
WO
WIPO (PCT)
Prior art keywords
active substance
substance combination
opioid
carbinol compound
compound
Prior art date
Application number
PCT/EP2005/003862
Other languages
French (fr)
Other versions
WO2005097192A9 (en
WO2005097192A2 (en
Inventor
Helmut Heinrich Buschmann
Silva Bonifacio Gutierrez
Joerg Holenz
Gomis Antonio Farre
Original Assignee
Esteve Labor Dr
Helmut Heinrich Buschmann
Silva Bonifacio Gutierrez
Joerg Holenz
Gomis Antonio Farre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200400836A external-priority patent/ES2245226B1/en
Priority claimed from US10/953,432 external-priority patent/US20050222135A1/en
Application filed by Esteve Labor Dr, Helmut Heinrich Buschmann, Silva Bonifacio Gutierrez, Joerg Holenz, Gomis Antonio Farre filed Critical Esteve Labor Dr
Priority to MXPA06011470A priority Critical patent/MXPA06011470A/en
Priority to JP2007506740A priority patent/JP2007531785A/en
Priority to EP05732430A priority patent/EP1755678A2/en
Priority to CA002562231A priority patent/CA2562231A1/en
Publication of WO2005097192A2 publication Critical patent/WO2005097192A2/en
Publication of WO2005097192A3 publication Critical patent/WO2005097192A3/en
Priority to US11/543,107 priority patent/US20070082893A1/en
Publication of WO2005097192A9 publication Critical patent/WO2005097192A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one opioid, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.
PCT/EP2005/003862 2004-04-05 2005-04-05 Active substance combination of a carbinol compound and an opioid WO2005097192A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA06011470A MXPA06011470A (en) 2004-04-05 2005-04-05 Active substance combination.
JP2007506740A JP2007531785A (en) 2004-04-05 2005-04-05 Active substance combination
EP05732430A EP1755678A2 (en) 2004-04-05 2005-04-05 Active substance combination of a carbinol compound and an opioid
CA002562231A CA2562231A1 (en) 2004-04-05 2005-04-05 Active substance combination of a carbinol compound and an opioid
US11/543,107 US20070082893A1 (en) 2004-04-05 2006-10-05 Active substance combination

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ES200400836A ES2245226B1 (en) 2004-04-05 2004-04-05 COMBINATION OF ACTIVE SUBSTANCES.
ES200400836 2004-04-05
ES200402102 2004-08-27
ES200402102 2004-08-27
US10/953,432 US20050222135A1 (en) 2004-04-04 2004-09-29 Active substance combination
US10/953,432 2004-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/543,107 Continuation US20070082893A1 (en) 2004-04-05 2006-10-05 Active substance combination

Publications (3)

Publication Number Publication Date
WO2005097192A2 WO2005097192A2 (en) 2005-10-20
WO2005097192A3 true WO2005097192A3 (en) 2006-03-30
WO2005097192A9 WO2005097192A9 (en) 2007-01-18

Family

ID=34964730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003862 WO2005097192A2 (en) 2004-04-05 2005-04-05 Active substance combination of a carbinol compound and an opioid

Country Status (4)

Country Link
EP (1) EP1755678A2 (en)
JP (1) JP2007531785A (en)
CA (1) CA2562231A1 (en)
WO (1) WO2005097192A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334548B1 (en) * 2005-07-29 2010-10-27 Laboratorios Del Dr. Esteve, S.A DOSAGE FORM OF CONTROLLED RELEASE OF PIRAZOL COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE.
WO2009005460A1 (en) * 2007-06-29 2009-01-08 Astrazeneca Ab Small molecule inhibitors of navl.7 sodium channels for the treatment of pain disorders
ES2350439B1 (en) * 2007-07-10 2011-10-17 Laboratorios Del Dr. Esteve, S.A. COMBINATION OF A BENCIL-4,5-DIHIDRO 1H-IMIDAZOL DERIVATIVE AND AN OPIOID RECEIVER.
EP2014288A1 (en) * 2007-07-10 2009-01-14 Laboratorios del Dr. Esteve S.A. Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850298A (en) * 1956-10-30 1960-10-05 Maggioni & C Societa Per Azion ª‡,ª‡[(p-chlorophenyl)-(4-pyridyl)] carbinols and method of preparing same
EP0289380A1 (en) * 1987-04-10 1988-11-02 Laboratorios Del Dr. Esteve, S.A. Aryl-heteroaryl-carbinol derivatives having an analgesic activity
US6118009A (en) * 1997-08-04 2000-09-12 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of cis-olirtine
WO2003099268A1 (en) * 2002-05-29 2003-12-04 Grünenthal GmbH Combination of selected opioids with other active substances for use in the therapy of urinary incontinence

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850298A (en) * 1956-10-30 1960-10-05 Maggioni & C Societa Per Azion ª‡,ª‡[(p-chlorophenyl)-(4-pyridyl)] carbinols and method of preparing same
EP0289380A1 (en) * 1987-04-10 1988-11-02 Laboratorios Del Dr. Esteve, S.A. Aryl-heteroaryl-carbinol derivatives having an analgesic activity
US6118009A (en) * 1997-08-04 2000-09-12 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of cis-olirtine
WO2003099268A1 (en) * 2002-05-29 2003-12-04 Grünenthal GmbH Combination of selected opioids with other active substances for use in the therapy of urinary incontinence

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MONCK N: "CIZOLIRTINE LABORATORIOS DR ESTEVE", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 2, no. 9, 2001, pages 1269 - 1272, XP009043627, ISSN: 0967-8298 *
SHEMBALKAR P ET AL: "CIZOLIRTINE CITRATE (E-4018) IN THE TREATMENT OF CHRONIC NEUROPATHIC PAIN", CURRENT MEDICAL RESEARCH AND OPINION, HANTS, GB, vol. 17, no. 4, 2001, pages 262 - 266, XP009043626 *

Also Published As

Publication number Publication date
JP2007531785A (en) 2007-11-08
CA2562231A1 (en) 2005-10-20
EP1755678A2 (en) 2007-02-28
WO2005097192A9 (en) 2007-01-18
WO2005097192A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
WO2006131721A3 (en) Topical ungual formulations
WO2006138735A3 (en) Gel compositions for topical administration
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2006091529A3 (en) A solid pharmaceutical dosage formulation
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2009117130A3 (en) Extended release forumulation containing a wax
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2005117895A3 (en) Compositions comprising meloxicam
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2007095043A3 (en) Pharmaceutical formulations
WO2007095039A3 (en) Pharmaceutical formulations
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007506740

Country of ref document: JP

Ref document number: PA/a/2006/011470

Country of ref document: MX

Ref document number: 2562231

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11543107

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005732430

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580018312.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005732430

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11543107

Country of ref document: US